Lineage Cell Therapeutics, Inc. (LCTX)
+0.020 (1.89%)
May 17, 2024, 4:00 PM EDT - Market closed

Company Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally.

The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.

In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology.

Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme.

The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019.

Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics logo
Country United States
Founded 1990
Industry Biotechnology
Sector Healthcare
Employees 68
CEO Brian M. Culley M.A., M.B.A.

Contact Details

2173 Salk Avenue, Suite 200
Carlsbad, California 92008
United States
Phone (510) 521-3390

Stock Details

Ticker Symbol LCTX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000876343
CUSIP Number 53566P109
ISIN Number US53566P1093
Employer ID 94-3127919
SIC Code 2836

Key Executives

Name Position
Brian M. Culley M.A., M.B.A. Chief Executive Officer, President and Director
Jill Ann Howe Chief Financial Officer and Principal Financial and Accounting Officer
George A. Samuel III, J.D. General Counsel and Company Secretary
Ioana C. Hone Director of Investor Relations
Brandi L. Roberts CPA, M.B.A. Consultant
William Annett MBA President and Chief Executive Officer of OncoCyte Corporation
Dr. Rami Skaliter Ph.D. Chief Executive Officer of Cell Cure Neurosciences
Alexandra Hernandez Senior Director of Finance and Controller
Dr. Harold D. Waitz Vice President of Regulatory Affairs and Quality Control

Latest SEC Filings

Date Type Title
May 14, 2024 EFFECT Notice of Effectiveness
May 14, 2024 8-K Current Report
May 14, 2024 424B5 Filing
May 9, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
Apr 29, 2024 ARS Filing
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Mar 22, 2024 424B5 Filing
Mar 22, 2024 8-K Current Report